On Thursday Sarepta Therapeutics (NASDAQ:SRPT) stock traded volume of 707202 shares during its last trading session as compared to its average volume of 1359626 shares over the recent month. SRPT ended its day with the below stream along the move of -1.02% and closed at the price of $83.06 before opening at $83.3. It has total market capitalization is $6174680218. 52 week range of the stock remained $ 72.05 – 158.8 while its day lowest price was $81.43 and its hit its day highest price at $84.2O
On Oct. 31, 2019, Sarepta Therapeutics (NASDAQ:SRPT) the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to eleven individuals hired by Sarepta in October 2019. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 14,270 shares of Sarepta’s common stock, and in the aggregate, 7,150 restricted stock units (RSUs). The options have an exercise price of $83.06 per share, which is equal to the closing price of Sarepta’s common stock on October 31, 2019 (the Grant Date). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for Limb-girdle muscular dystrophy diseases (LGMD), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases.
Cheyenne Cox is a news report covering multiple Market and economy News. She is creative and highly professional writer. Cheyenne holds a degree in communication and journalism and has also a Diploma in digital marketing. She belongs to south Africa who has also lived in Europe and is currently based in the US.
